Johnson & Johnson (JNJ) EPS (Weighted Average and Diluted) (2009 - 2026)

Johnson & Johnson's EPS (Weighted Average and Diluted) history runs 18 years deep, the most recent figure standing at $2.14 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) fell 52.86% year-over-year to $2.14; the TTM figure through Mar 2026 stood at $8.64 (down 3.89% YoY), while the FY2025 annual figure was $11.03, up 90.5% from the prior year.
• EPS (Weighted Average and Diluted) came in at $2.14 for Q1 2026 at Johnson & Johnson, up from $2.09 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $10.21 in Q4 2023 to a low of -$0.09 in Q3 2023.
• A 5-year average of $2.2 and a median of $1.8 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
• Across the five-year window, EPS (Weighted Average and Diluted) sank 104.9% in 2023 and soared 4566.67% in 2024, its largest moves.
• Johnson & Johnson's EPS (Weighted Average and Diluted) stood at $1.68 in 2022, then climbed by 1.19% to $1.7 in 2023, then slipped by 17.06% to $1.41 in 2024, then jumped by 48.23% to $2.09 in 2025, then gained by 2.39% to $2.14 in 2026.
• According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered $2.14, $2.09, and $2.12 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison